Table 5.
3-Year Incidence of Neurocognitive Diagnoses Among Patients With Systolic HF Receiving Sacubitril/Valsartan vs Propensity Score-Matched Patients Receiving ACEIs or ARBs in Racial Subgroups
| Sacubitril/Valsartan (n = 7,629)a |
ACEI/ARB (n = 7,629)a |
HR (95% CI) | P Value | |||
|---|---|---|---|---|---|---|
| Events | 3-y K-M Estimate | Events | 3-y K-M Estimate | |||
| White | ||||||
| Primary endpoint | 631 | 11.8% | 816 | 15.0% | 0.75 (0.68-0.84) | <0.001 |
| Cognitive decline | 556 | 10.4% | 730 | 13.1% | 0.75 (0.67-0.83) | <0.001 |
| Dementia | 223 | 4.0% | 302 | 5.4% | 0.74 (0.62-0.88) | 0.001 |
| Alzheimer’s disease | 47 | 0.8% | 77 | 1.3% | 0.62 (0.43-0.89) | 0.008 |
| Sacubitril/Valsartan (n = 2,423)a |
ACEI/ARB (n = 2,423)a |
HR (95% CI) | P Value | |||
|---|---|---|---|---|---|---|
| Events | 3-y K-M Estimate | Events | 3-y K-M Estimate | |||
| Black | ||||||
| Primary endpoint | 157 | 8.8% | 259 | 14.6% | 0.60 (0.49-0.73) | <0.001 |
| Cognitive decline | 151 | 8.4% | 241 | 13.5% | 0.62 (0.51-0.76) | <0.001 |
| Dementia | 37 | 1.9% | 63 | 3.3% | 0.60 (0.40-0.89) | 0.011 |
| Alzheimer’s disease | 10 | 0.4% | 15 | 0.8% | 0.48 (0.19-1.17) | 0.097 |
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; HF = heart failure; K-M = Kaplan-Meier.
a
Patients with prevalent diagnoses of interest at baseline were excluded from calculation of incidence for each analysis.